Trending

Humira

AbbVie, Pfizer reach licencing agreement for biosimilar Humira

AbbVie, Pfizer reach licencing agreement for biosimilar Humira

AbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries

X

AbbVie, Pfizer reach licencing agreement for biosimilar Humira

https://pharmaphorum.com/news/abbvie-pfizer-reach-licencing-agreement-for-biosimilar-humira/

Has the NHS joined the biosimilars revolution?

Has the NHS joined the biosimilars revolution?

Biosimilars have cut the price of biologic drugs by up to 80% on the NHS, according to Paul

X

Has the NHS joined the biosimilars revolution?

https://pharmaphorum.com/oncology/nhs-joined-biosimilar-revolution/

FDA approves biosimilar of blockbuster Humira

FDA approves biosimilar of blockbuster Humira

A Humira biosimilar, produced by drug maker Sandoz, has been given the green light from the US Food

X

FDA approves biosimilar of blockbuster Humira

https://pharmaphorum.com/news/fda-approves-biosimilar-blockbuster-humira/

AbbVie braces for impact of Humira biosimilars in Europe

AbbVie braces for impact of Humira biosimilars in Europe

AbbVie looks set to lose several billion dollars in revenue from Humira, as its soon to expire European

X

AbbVie braces for impact of Humira biosimilars in Europe

https://pharmaphorum.com/news/abbvie-braces-for-impact-of-humira-biosimilars-in-europe/

Fourth Humira biosimilar set for EU approval

Fourth Humira biosimilar set for EU approval

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s

X

Fourth Humira biosimilar set for EU approval

https://pharmaphorum.com/news/humira-biosimilar-eu-sandoz-chmp/

Payday for AbbVie as Humira biosimilar delayed for five years

Payday for AbbVie as Humira biosimilar delayed for five years

Deal with Amgen signals exclusivity until 2023 for mega-blockbuster

X

Payday for AbbVie as Humira biosimilar delayed for five years

https://pharmaphorum.com/news/no-us-humira-biosimilar-likely-another-five-years/

AbbVie bullish on Humira and near-term pipeline

AbbVie bullish on Humira and near-term pipeline

Sales of Humira could peak above $18 billion – CEO

X

AbbVie bullish on Humira and near-term pipeline

https://pharmaphorum.com/news/abbvie-looks-beyond-humira/

Amjevita, first Humira biosimilar approved – but no launch yet

Amjevita, first Humira biosimilar approved – but no launch yet

Amgen’s biosimilar is ready to go, but AbbVie believes it can delay until 2022

X

Amjevita, first Humira biosimilar approved – but no launch yet

https://pharmaphorum.com/news/humira-biosimilar-approved/

AbbVie waits on data from Humira successor

AbbVie waits on data from Humira successor

Ablynx’s vobarilizumab seen as key should Humira sales fall.

X

AbbVie waits on data from Humira successor

https://pharmaphorum.com/news/abbvie-waits-data-humira-successor/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com